CMRM6122

TYRX™ absorbable antibacterial envelope — size: medium, length: 6.3 cm, width: 6.9 cm

The TYRX™ absorbable antibacterial envelope is used with cardiac implantable electronic devices, including implantable cardioverter defibrillators.

Contact a representative

Indications, Safety, and Warnings

Description

Proven protection, proven performance

Demonstrated CIED stabilization and infection reduction^1–9
Locally-delivered minocycline and rifampin sustained for 7 days¹⁰
Polymer-controlled antibiotic elution¹⁰
Multifilament-knitted mesh fully absorbs in approximately 9 weeks^10,11

Tarakji KG, Mittal S, Kennergren C, et al. Antibacterial envelope to prevent cardiac implantable device infection. N Engl J Med. 2019;380(20):1895–1905.
Huntingdon Life Sciences study TR-2011-054.
Osoro M, Lorson W, Hirsh JB, Mahlow WJ. Use of an antimicrobial pouch/envelope in the treatment of Twiddler’s syndrome. Pacing Clin Electrophysiol. 2018;41(2):136–142.
Bloom HL, Constantin L, Dan D, et al. Implantation success and infection in cardiovascular implantable electronic device procedures utilizing an antibacterial envelope. Pacing Clin Electrophysiol. 2011;34(2):133–142.
Mittal S, Shaw RE, Michel K, et al. Cardiac implantable electronic device infections: incidence, risk factors, and the effect of the AigisRx antibacterial envelope. Heart Rhythm. 2014;11(4):595–601.
Kolek MJ, Patel NJ, Clair WK, et al. Efficacy of a bio-absorbable antibacterial envelope to prevent cardiac implantable electronic device Infections in high-risk subjects. J Cardiovasc Electrophysiol. 2015;26(10):1111–1116.
Shariff N, Eby E, Adelstein E, et al. Health and economic outcomes associated with use of an antimicrobial envelope as a standard of care for cardiac implantable electronic device implantation. J Cardiovasc Electrophysiol. 2015;26(7):783–789.
Henrikson CA, Sohail MR, Acosta H, et al. Antibacterial envelope is associated with low infection rates after implantable cardioverter-defibrillator and cardiac resynchronization therapy device replacement: Results of the Citadel and Centurion studies. JACC Clin Electrophysiol. 2017;3(10):1158–1167.
Kolek MJ, Dresen WF, Wells QS, Ellis CR. Use of an antibacterial envelope is associated with reduced cardiac implantable electronic device infections in high-risk patients. Pacing Clin Electrophysiol. 2013;36(3):354–361.
Huntingdon Life Sciences study TR-2013–001.
Sinclair Labs study D13599.

Not what you're looking for?

Find more information, including other available configurations, for TYRX™ absorbable antibacterial envelope.

First Name

Last Name

Hospital Or Organization

Job Role

Specialty

Confirm country/region

Just to confirm, is this the product or product type that interests you?

{{productNamePlaceholder}}

Confirm country/region

Before we get started, what best describes you?

Confirm country/region

Before we get started, what best describes you?

First Name

Last Name

Hospital Or Organization

HOSPITAL POSTAL CODE

Job Role

Specialty

First Name

Last Name

PHONE

Hospital Or Organization

HOSPITAL POSTAL CODE

Job Role

Specialty

CMRM6122

TYRX™ absorbable antibacterial envelope — size: medium, length: 6.3 cm, width: 6.9 cm

CMRM6122

TYRX™ absorbable antibacterial envelope — size: medium, length: 6.3 cm, width: 6.9 cm

Description

Proven protection, proven performance

Not what you're looking for?

United States

Customer Care Team

CMRM6122 TYRX™ absorbable antibacterial envelope — size: medium, length: 6.3 cm, width: 6.9 cm

CMRM6122 TYRX™ absorbable antibacterial envelope — size: medium, length: 6.3 cm, width: 6.9 cm

Description

Proven protection, proven performance

Not what you're looking for?

United States

Customer Care Team

CMRM6122

TYRX™ absorbable antibacterial envelope — size: medium, length: 6.3 cm, width: 6.9 cm

CMRM6122

TYRX™ absorbable antibacterial envelope — size: medium, length: 6.3 cm, width: 6.9 cm